Answers are grounded in this paper and cite their sources.
Microtubules (MT) are dynamically instable, assembling and disassembling structures of the cell. Tubulin, the major building protein of MT, is a heterodimer consisting of α and ẞ subunits. Agents that bind to tubulin and inhibit its assembly lead to the inhibition of MT formation. Such tubulin-binding agents are usually termed MT-disassembling agents or antitubulins. Endocytosis, matrix protein secretion, cell division, cell migration and inflammation are examples of MT-dependent processes. Their dysfunction, in particular in arterial smooth muscle cells (ASMC), is critically involved in atherogenesis. Here we Dance round (i) MT-based secretory pathway in ASMC and, in turn, antitubulins for atherosclerosis therapy, and (ii) the neurotrophins, particularly nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) and their receptors Trk (tyrosine receptor kinase; pronounced `track`), introducing the term trackins - Trk-targeting agents (TTA) that influence positively (agonistically) or negatively (antagonistically) the activity of TrkA receptor for NGF and/or TrkB receptor for BDNF. We propose that some trackins and their native ligands may have therapeutic potentials for cardiometabolic, neuropsychiatric, oncologic and other diseases. Finally the interaction of MT-tubulin and neurotrophin Trk receptors is outlined.
No takes yet. Share an insight, caveat, or question.
Yanev et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: